大剂量舒肝解郁胶囊治疗中度抑郁症疗效及对血清单胺类神经递质、社会功能改善和免疫功能的影响-国际精神病学杂志-CSCIED科技核心评价数据库-手机版

大剂量舒肝解郁胶囊治疗中度抑郁症疗效及对血清单胺类神经递质、社会功能改善和免疫功能的影响

Curative effect of high-dose Shuganjieyu capsule on moderate depression and the effect on serum monoamine neurotransmitters, social function and immune function

ES评分 0 浏览量：512 下载量：0

全文阅读下载引用收藏

DOI
刊名	国际精神病学杂志 Journal of International Psychiatry
年，卷(期)	2018, 45(3)
作者	李静*,李晓红,杨旭宁,汤育林,李文波,
作者单位	河南省洛阳荣康医院药剂科 ; 洛阳市中心医院精神科 ;
摘要	摘要目的：观察大剂量舒肝解郁胶囊治疗中度抑郁症疗效及对血清单胺类神经递质、社会功能改善和免疫功能的影响。方法：将160例中度抑郁症患者随机分为对照组和观察组，每组80例；对照组给予常规剂量（2粒/次，2次/天）舒肝解郁胶囊治疗，观察组给予大剂量（4粒/次，2次/天）舒肝解郁胶囊治疗，比较两组治疗效果。结果：治疗后各时间点（治疗后2周、4周、6周、8周），观察组汉密尔顿17项抑郁量表（HAMD-17）评分、汉密尔顿焦虑量表（HAMA）评分均明显低于对照组（P <0.05）；治疗8周后，观察组较对照组中医症候积分、认知功能成套测验（MCCB）量表评分均明显降低（P <0.05），住院精神病人社会功能评定量表（SSFPI）评分明显升高（P <0.05）；治疗8周后，观察组较对照组外周血CD3+、CD4+、CD4+/CD8+及血清多巴胺（DA）、去甲肾上腺素（NE）、5-羟色胺（5-HT）水平明显升高，差异均有统计学意义（P <0.05）。两组不良反应发生率比较（18.75%vs13.75%）无显著差异（2=0.735，P<0.05），且均为轻中度不良反应，患者可耐受。结论：大剂量舒肝解郁胶囊治疗中度抑郁症疗效显著，可有效调节血清单胺类神经递质水平，明显缓解患者抑郁症状，改善社会功能及免疫功能，且安全性尚可。
Abstract	Abstract Objective: To observe the curative effect of high-dose Shuganjieyu capsule on moderate depression and the effect on serum monoamine neurotransmitters, social function and immune function. Methods: A total of 160 patients with moderate depression were randomly divided into the control group and the observation group, 80 patients in each group. The control group was treated with routine dose (2 capsules/times, twice / day) Shuganjieyu capsule while the observation group was treated with high-dose (4 capsules/times, twice / day) of Shuganjieyu capsule. The curative effect was compared between the two groups. Results: Scores of the 17-item Hamilton Rating Scale for Depression (HAMD-17) and Hamilton Anxiety Scale (HAMA) in the observation group at different time points after treatment were significantly lower than those in the control group (P <0.05). After 8 weeks of treatment, the TCM syndrome score and the MATRICS consensus cognitive battery (MCCB) score in the observation group were significantly lower than those in the control group (P <0.05), while the score of social function in in-patients with psychosis (SSFPI) was significantly higher than that in the control group (P <0.05). After 8 weeks of treatment, peripheral blood levels of CD3+, CD4+ and CD4+/CD8+ and serum levels of dopamine (DA), norepinephrine (NE) and 5- hydroxytryptamine (5-HT) in the observation group were significantly higher than those in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (18.75% vs13.75%) (x2=0.735, P<0.05), and adverse reactions in both groups were mild and moderate and the patients could tolerate. Conclusion: High-dose Shuganjieyu capsule is significantly effective in the treatment of moderate depression. It can effectively regulate the serum levels of monoamine neurotransmitters, alleviate the depressive symptoms, and improve the social function and immune function in patients.
关键词	关键词中度抑郁症；大剂量舒肝解郁胶囊；神经递质；社会功能；免疫功能
KeyWord	Key words Moderate depression; High-dose Shuganjieyu capsule; Neurotransmitter; Social function; Immune function
基金项目
页码	491-493

参考文献
相关文献

引用本文

李静*,李晓红,杨旭宁,汤育林,李文波. 大剂量舒肝解郁胶囊治疗中度抑郁症疗效及对血清单胺类神经递质、社会功能改善和免疫功能的影响 [J]. 国际精神病学杂志. 2018; 45; (3). 491 - 493.

文献评论

相关学者

相关机构